Orlistat/alli program

PreclinicalSmall molecule

SStanford University

Orlistat/alli program is one of 15 small molecule programs targeting Eating Disorder. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Eating DisorderActive, not recruiting

Eating DisorderPreclinical

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Eating Disorder

#DrugCompanyPhaseTrials

Namenda

AbbVie

Approved

1 2

Atarax

Pfizer

Approved

1 3

Cymbalta

Jazz Pharmaceuticals

Approved

1 4

Victoza

Novo Nordisk

Approved

—5

Sunosi

AAxsome Therapeutics, Inc.

Approved

1 6

Strattera

MMap77

Approved

1 7

E-Mycin

AAzurity Pharmaceuticals

Approved

—8

Zonegran

AAzurity Pharmaceuticals

Zyprexa

Adzenys Er

AAzurity Pharmaceuticals

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Eating Disorder1 trial

Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder

Completed·SStanford University·N/A·NCT00601354·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Orlistat/alli program. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Orlistat/alli program compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Orlistat/alli program. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SStanford University

Orlistat/alli program

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Eating Disorder1 trial

References

Drug Info

Quick Facts

Related News